The cost-effectiveness of nirsevimab and maternal RSV vaccines in reducing health care costs and productivity losses associated with RSV was analyzed. Nirsevimab could prevent 14,341 hospitalizations and 14 deaths per year, while the maternal vaccine could prevent 7,571 hospitalizations and 8 deaths per year. Both vaccines were found to increase overall spending, but reduce societal costs related to RSV infection. The cost per QALY gained for nirsevimab was $153,517, while for the maternal vaccine it was $396,280. Combining both vaccines showed increased costs due to marginal additional protection. Various scenarios and factors were considered to determine the cost-effectiveness of each vaccine.
Source link
Nirsevimab, maternal vaccine reduce medical spending for RSV
